Peripheral Neuropathic Pain - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides an overview of the Peripheral Neuropathic Pain (Central Nervous System) pipeline landscape.

Peripheral neuropathic pain is a chronic pain state that usually is accompanied by tissue injury. Causes include alcoholism, diabetes, chemotherapy, infections, surgery and multiple sclerosis. Symptoms include burning pain, tingling and numbness. Treatment includes non-steroidal anti-inflammatory drugs, anticonvulsant and antidepressant drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peripheral Neuropathic Pain Overview 7
Therapeutics Development 8
Pipeline Products for Peripheral Neuropathic Pain - Overview 8
Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis 9
Peripheral Neuropathic Pain - Therapeutics under Development by Companies 10
Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 11
Peripheral Neuropathic Pain - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Peripheral Neuropathic Pain - Products under Development by Companies 15
Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes 16
Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development 17
Achelios Therapeutics, Inc. 17
AnaBios Corporation 18
Chromocell Corporation 19
GW Pharmaceuticals Plc 20
Nektar Therapeutics 21
Phosphagenics Limited 22
Spherium Biomed S.L. 23
Sunovion Pharmaceuticals Inc. 24
Yuhan Corporation 25
Zynerba Pharmaceuticals, Inc. 26
Peripheral Neuropathic Pain - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AXPN-03 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CC-8464 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DSP-2230 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ECL-1 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ketoprofen - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
nabiximols - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
NKTR-171 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ORP-101 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
oxycodone ER - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
pregabalin CR - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule for Pain - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
SP-15001 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ZYN-001 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Peripheral Neuropathic Pain - Dormant Projects 63
Peripheral Neuropathic Pain - Discontinued Products 64
Peripheral Neuropathic Pain - Product Development Milestones 65
Featured News & Press Releases 65
Oct 12, 2016: FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN 65
Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Peripheral Neuropathic Pain, H2 2016 8
Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H2 2016 17
Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2016 18
Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016 19
Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 20
Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2016 21
Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2016 22
Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H2 2016 23
Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 24
Peripheral Neuropathic Pain - Pipeline by Yuhan Corporation, H2 2016 25
Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Peripheral Neuropathic Pain - Dormant Projects, H2 2016 63
Peripheral Neuropathic Pain - Discontinued Products, H2 2016 64